tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

OVID Stock Latest News

Ovid Therapeutics price target lowered to $4 from $5 at BTIG
The FlyOvid Therapeutics price target lowered to $4 from $5 at BTIG
5d ago
OVID
Ovid Therapeutics: Strategic Pipeline Reprioritization and Promising KCC2 Portfolio Drive Buy Rating
PremiumRatings
Ovid Therapeutics: Strategic Pipeline Reprioritization and Promising KCC2 Portfolio Drive Buy Rating
5d ago
OVID
Ovid Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
PremiumThe Fly
Ovid Therapeutics price target lowered to $2 from $3 at H.C. Wainwright
5d ago
OVID
Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer
PremiumThe Fly
Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer
10d ago
APLT
OVID
Ovid Therapeutics price target lowered to $3 from $4 at Wedbush
PremiumThe Fly
Ovid Therapeutics price target lowered to $3 from $4 at Wedbush
17d ago
OVID
Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies
PremiumCompany AnnouncementsOvid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies
17d ago
OVID
Ovid Therapeutics sees cash runway into 2H26
Premium
The Fly
Ovid Therapeutics sees cash runway into 2H26
18d ago
OVID
Ovid Therapeutics reports Q4 EPS (13c), consensus (17c)
Premium
The Fly
Ovid Therapeutics reports Q4 EPS (13c), consensus (17c)
18d ago
OVID
Ovid Therapeutics Expands Board with New Appointment
PremiumCompany Announcements
Ovid Therapeutics Expands Board with New Appointment
24d ago
8K
OVID
Ovid Therapeutics appoints Papadopoulos to board of directors
PremiumThe Fly
Ovid Therapeutics appoints Papadopoulos to board of directors
26d ago
OVID
Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’
PremiumThe Fly
Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’
2M ago
OVID
Ovid Therapeutics upgraded to Outperform from Perform at Oppenheimer
PremiumThe Fly
Ovid Therapeutics upgraded to Outperform from Perform at Oppenheimer
2M ago
OVID
Ovid to present posters on pipeline program for neuronal hyperexcitability
PremiumThe FlyOvid to present posters on pipeline program for neuronal hyperexcitability
4M ago
OVID
Ovid Therapeutics reports Q3 EPS (20c), consensus (20c)
Premium
The Fly
Ovid Therapeutics reports Q3 EPS (20c), consensus (20c)
5M ago
OVID
Ovid Therapeutics presents study results on OV329
Premium
The Fly
Ovid Therapeutics presents study results on OV329
6M ago
OVID
Ovid Therapeutics Elevates Meg Alexander to President and COO
PremiumCompany Announcements
Ovid Therapeutics Elevates Meg Alexander to President and COO
7M ago
8K
OVID
Ovid Therapeutics appoints Alexander as President, COO
PremiumThe Fly
Ovid Therapeutics appoints Alexander as President, COO
7M ago
OVID
Ovid Therapeutics actively evaluating pipeline
PremiumThe Fly
Ovid Therapeutics actively evaluating pipeline
8M ago
OVID
Ovid Therapeutics reduces headcount by 43%
PremiumThe Fly
Ovid Therapeutics reduces headcount by 43%
8M ago
OVID
Ovid Therapeutics reports cash position of $77M as of June 30
PremiumThe FlyOvid Therapeutics reports cash position of $77M as of June 30
8M ago
OVID
Ovid Therapeutics reports Q2 EPS 12c, consensus (22c)
Premium
The Fly
Ovid Therapeutics reports Q2 EPS 12c, consensus (22c)
8M ago
OVID
Ovid Therapeutics appoints Banks as Chief Development Officer
Premium
The Fly
Ovid Therapeutics appoints Banks as Chief Development Officer
8M ago
OVID

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >